Compare Intuitive Surgical, Inc. (ISRG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Mesoblast Limited — how do they compare? Intuitive Surgical, Inc. trades at $425.1 (market cap $146.76B), while Mesoblast Limited trades at $14.31 (market cap $1.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 83.9× Mesoblast Limited's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Mesoblast Limited for 14 Days on average.
| ISRG | MESO | |
|---|---|---|
Market Cap | $146.76B | $1.75B |
Volume | 2,529,814 | 239,027 |
Sector | Health | Health |
52-Week High | $592.85 | $20.96 |
52-Week Low | $332.02 | $13.19 |
Typical Hold Time | 84 Days | 14 Days |
Enterprise Value | $141.54B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% today, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $6.2B in 2022 to $10.1B in 2025 and net income margin expanding to 28.45%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast.
ISRG maintains a dominant position in robotic surgery with expanding international growth, though valuation multiples remain elevated with a P/E of 47.64. Analyst consensus is strongly bullish with a $480.78 price target representing 16% upside potential. Key risks include competitive pressures and international market volatility, particularly in China.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
